BACKGROUND/AIMS: Glycogen storage disease III (GSD III) is caused by a deficiency of glycogen-debranching enzyme which causes an incomplete glycogenolysis resulting in glycogen accumulation with abnormal structure (short outer chains resembling limit dextrin) in liver and muscle. Hepatic involvement is considered mild, self-limiting and improves with age. With increased survival, a few cases of liver cirrhosis and hepatocellular carcinoma (HCC) have been reported. METHODS: A systematic review of 45 cases of GSD III at our center (20 months to 67 years of age) was reviewed for HCC, 2 patients were identified. A literature review of HCC in GSD III was performed and findings compared to our patients. CONCLUSIONS: GSD III patients are at risk for developing HCC. Cirrhosis was present in all cases and appears to be responsible for HCC transformation There are no reliable biomarkers to monitor for HCC in GSD III. Systematic evaluation of liver disease needs be continued in all patients, despite lack of symptoms. Development of guidelines to allow for systematic review and microarray studies are needed to better delineate the etiology of the hepatocellular carcinoma in patients with GSD III.
BACKGROUND/AIMS: Glycogen storage disease III (GSD III) is caused by a deficiency of glycogen-debranching enzyme which causes an incomplete glycogenolysis resulting in glycogen accumulation with abnormal structure (short outer chains resembling limit dextrin) in liver and muscle. Hepatic involvement is considered mild, self-limiting and improves with age. With increased survival, a few cases of liver cirrhosis and hepatocellular carcinoma (HCC) have been reported. METHODS: A systematic review of 45 cases of GSD III at our center (20 months to 67 years of age) was reviewed for HCC, 2 patients were identified. A literature review of HCC in GSD III was performed and findings compared to our patients. CONCLUSIONS:GSD III patients are at risk for developing HCC. Cirrhosis was present in all cases and appears to be responsible for HCC transformation There are no reliable biomarkers to monitor for HCC in GSD III. Systematic evaluation of liver disease needs be continued in all patients, despite lack of symptoms. Development of guidelines to allow for systematic review and microarray studies are needed to better delineate the etiology of the hepatocellular carcinoma in patients with GSD III.
Authors: Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit Journal: Eur J Pediatr Date: 2002-08-22 Impact factor: 3.183
Authors: J Shimizu; H Shiraishi; S Sakurabayashi; F Sugiura; H Takizawa; K Miyazaki; Y Matsumoto; Y Nishizato; T Sato; Y Watanabe; S Masuda; Y Watanbe; Y Otaka; T Sakiyama; T Kitagawa; S Mizuguchi; S Ashizawa Journal: Nihon Shokakibyo Gakkai Zasshi Date: 1982-12
Authors: M Siciliano; E De Candia; S Ballarin; F M Vecchio; S Servidei; R Annese; R Landolfi; L Rossi Journal: J Clin Gastroenterol Date: 2000-07 Impact factor: 3.062
Authors: D Matern; T E Starzl; W Arnaout; J Barnard; J S Bynon; A Dhawan; J Emond; E B Haagsma; G Hug; A Lachaux; G P Smit; Y T Chen Journal: Eur J Pediatr Date: 1999-12 Impact factor: 3.183
Authors: Joseph L Sottnik; Vandana Mallaredy; Ana Chauca-Diaz; Carolyn Ritterson Lew; Charles Owens; Garrett M Dancik; Serena Pagliarani; Sabrina Lucchiari; Maurizio Moggio; Michela Ripolone; Giacomo P Comi; Henry F Frierson; David Clouthier; Dan Theodorescu Journal: Carcinogenesis Date: 2019-03-12 Impact factor: 4.944
Authors: Haiqing Yi; Elizabeth D Brooks; Beth L Thurberg; John C Fyfe; Priya S Kishnani; Baodong Sun Journal: J Mol Med (Berl) Date: 2014-02-08 Impact factor: 4.599